Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 28, 2015 10:35 AM ET

Healthcare Equipment and Supplies

Company Overview of Alcon Laboratories, Inc.

Company Overview

Alcon Laboratories, Inc. manufactures, markets and distributes eye care products. The company offers ophthalmic pharmaceuticals, surgical equipment, and contact lenses. Its products include ophthalmic solutions and suspensions, eye drops, otic suspensions, contact lens solutions, and eye vitamins. The company also offers contact lenses and surgical devices for cataract, glaucoma, vitreoretinal, and refractive treatment. The company was founded in 1945 and is based in Fort Worth, Texas. Alcon Laboratories, Inc. operates as a subsidiary of Alcon, Inc.

6201 South Freeway

Fort Worth, TX 76134-2099

United States

Founded in 1945

Phone:

817-293-0450

Fax:

817-551-4696

Key Executives for Alcon Laboratories, Inc.

President
Age: 40
Senior Vice President of Global Manufacturing and Technical Operations
Age: 53
Senior Vice President, Chief Legal Officer, General Counsel, and Corporate Secretary
Age: 59
Senior Vice President of Human Resources
Senior Vice President of International Markets
Compensation as of Fiscal Year 2014.

Alcon Laboratories, Inc. Key Developments

A Prominent Fort Worth Resident Files $110 Million Gender Discrimination Suit Against Alcon Laboratris Inc

A Fort Worth resident filed a $110 million gender discrimination suit against Alcon Laboratris Inc. claiming the eye-care products company routinely denied female employees equal pay and promotion opportunities. Elyse Dickerson, wife of the curator at the Kimbell Art Museum, and Susan Orr, claim in the suit that Alcon has a "boy's club atmosphere" that's hostile to women. The new suit claims that 12 of 15 members of Alcon's executive leadership team are men, including the global head of Alcon, Jeff George, as well as the chief financial officer, all five region presidents and the senior vice president for human resources. Women make up fewer than 15% of vice presidents and senior directors in Novartis' Alcon division. A current Executive Leadership Team member repeatedly arranged for prostitutes to meet with doctors viewed by the company as "key opinion leaders" but was never disciplined or demoted for doing so, the suit says. Male senior leaders invited younger male employees to visit strip clubs, play golf, and drink at bars, but female employees were rarely invited, the lawsuit says. Dickerson and Orr say in the suit that the company violated the U.S. Equal Pay Act and Title VII of the Civil Rights Act of 1964, which prohibits gender discrimination by employers. Dickerson says in the suit that she was fired from her job as a global director for complaining about what she saw as inequities at the company. She is seeking $10 million and her job back. Orr, a research scientist, says the lack of promotions forced her to resign. She's seeking at least $100 million on behalf of a proposed class of thousands of Alcon employees who are women.

Fda Approves Alcon Laboratories, Inc.'s Xtoro to Treat Swimmer’s Ear

The U.S. Food and Drug Administration approved Xtoro (finafloxacin otic suspension), a new drug used to treat acute otitis externa, commonly known as swimmer's ear. Acute otitis externa is an infection in the outer ear and ear canal, usually caused by bacteria in the ear canal. Activities in which the ear is underwater can create a moist environment where bacteria may sometimes grow. The infection causes inflammation of the ear canal leading to pain, swelling, redness of the ear and discharge from the ear. Xtoro is an eardrop approved to treat acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus. Xtoro is the newest drug belonging to the fluoroquinolone antimicrobial drug class to be approved by the FDA. It joins several other antibacterial drug products previously approved to treat ear infections. Xtoro is manufactured Alcon Laboratories, Inc.

Alcon Laboratories Wins $2.76 Million Federal Contract

Alcon Laboratories won a $275,759.39 federal contract from the U.S. Department of Veterans Affairs, Ridgeland, Mississippi, for phacoemulsification surgical equipment.

Similar Private Companies By Industry

Company Name Region
Applied Fiberoptics, Inc. United States
CleveX, Inc. United States
Nuclear Resources, Inc. United States
Responselink, LLC United States
Photetica Incorporated United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alcon Laboratories, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.